Login to Your Account

FDA Approves NuPathe Migraine Patch, 4Q Launch Planned

By Marie Powers
Staff Writer

Tuesday, January 22, 2013
After seven years of development, NuPathe Inc. finally received a green light from the FDA for its sumatriptan patch, branded Zecuity (sumatriptan iontophoretic transdermal system), for the acute treatment of migraine with or without aura in adults.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription